Recent News

• 11.06.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 11.03.2026 - BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
• 10.29.2026 - BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
• 10.22.2026 - BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
• 10.16.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 10.11.2026 - Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
• 10.11.2026 - Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
• 10.06.2026 - BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
• 10.06.2026 - BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
• 10.06.2026 - BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

Recent Filings

• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.29.2026 - EX-99.1 EX-99.1
• 10.29.2026 - 8-K Current report
• 10.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.13.2026 - 8-K Current report
• 10.13.2026 - EX-99.1 EX-99.1
• 09.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.31.2026 - 8-K Current report
• 08.31.2026 - EX-99.1 EX-99.1